Journal
INFLAMMATORY BOWEL DISEASES
Volume 22, Issue 11, Pages 2733-2747Publisher
OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000000923
Keywords
azathioprine; 6-mercaptopurine; thiopurines; inflammatory bowel disease; therapy
Categories
Funding
- Vifor Pharma
- AbbVie
- Falk
- MSD
- Takeda
- UCB Pharma
- Tillotts
- Receptos
- Regeneron
- Nestle Health Sciences
- Amgen
- AstraZeneca
- Calypso
- Delenex
- Ferring
- Hospira
- Merck-Serono
- Pfizer
- UCB
- Augurix
- Boehringer
- Fisher
- Genentech
- Essex/MSD
- Novartis
- Phadia
- Roche
- Vital Solutions
- Zeller
- Ardeypharm
- Flamentera
- Dr Falk pharma
- Atlantic Healthcare
Ask authors/readers for more resources
The relevance of azathioprine and 6-mercaptopurine therapy in inflammatory bowel disease, Crohn's disease, and ulcerative colitis, has been challenged in recent publications. In this article, a panel of experts gives advice, based on the relevant literature, on indications and practical use of azathioprine/6-mercaptopurine, prevention, and management of drug adverse reactions and special situations such as vaccination, pregnancy, and lactation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available